
Castle Biosciences fell 11.8% from $37.88 to $33.41, behind the S&P 500's +4.7%. Its worst day was May 7 (−22.3%), and its low came May 13 at $18.15.
Nov 21, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Castle Biosciences closed at its highest level of the year, 13.6% above where the year started.
+1.9% · S&P 500 +0.5%
Castle Biosciences shares fell 10.2%, while the S&P 500 fell 0.5%.
−10.2% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.08 beat the $-0.24 estimate on $87.0M revenue (est. $80.3M); FY revenue guidance of $340.0M–$350.0M against the $335.0M consensus.
−7.2% · S&P 500 −0.5%
EPS of $-0.49 beat the $-0.50 estimate on $83.7M revenue (est. $79.7M); FY revenue guidance of $345.0M–$355.0M against the $346.3M consensus.
−22.3%, the year's worst day, on 2M shares, the year's heaviest volume · S&P 500 −0.3%
EPS of $-0.07 beat the $-0.41 estimate on $103.5M revenue (est. $86.6M); FY revenue guidance of $365.0M–$375.0M against the $353.2M consensus.
+4.5% · S&P 500 +0.7%
Castle Biosciences shares rose 11.3%, while the S&P 500 rose 0.2%.
+11.3%, the year's best day · S&P 500 +0.2%
Castle Biosciences shares fell 9.0%, while the S&P 500 rose 0.5%.
−9.0% · S&P 500 +0.5%
EPS of $-0.13 beat the $-0.35 estimate on $102.9M revenue (est. $92.7M); FY revenue guidance of $385.0M–$395.0M against the $374.7M consensus.
−4.9% · S&P 500 +0.3%
Where it ended: a close of $33.41 on Nov 19, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.14, revenue est. $102.4M).
Nothing in the past 12 months.
All CSTL dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CSTL and SPY from Benzinga historical bars. Not investment advice.